Program
ATA Annual Meeting Program/Schedule at a Glance
The ATA Annual Meeting Program Committee is actively planning the Plenaries, Symposia and Meet the Professor/Scientist Sessions. The preliminary schedule is listed below and is subject to change.
Basic Science Track
This year’s program has a dedicated programming track for basic scientists. Click here to learn more.
Wednesday, September 27, 2023
1:00 PM – 5:45 PM
Registration Open
7:00 AM – 4:30 PM
Endocrine Neck Advanced Ultrasound Course (REACHED REGISTRATION CAPACITY)
9:00 AM – 5:00 PM
Ridgway Trainees’ Conference (Included with Trainee registration for annual meeting. Additional fee for other registration categories.)
7:30 AM – 3:00 PM
Leadership Development Workshop (additional registration fee)
8:45 AM -4:00 PM
Interventional Endocrinology Workshop (additional registration fee)
3:30 PM – 5:30 PM
ATA Committee Meetings
After 5:30 PM
NETWORKING/DINNER ON YOUR OWN
Thursday, September 28, 2023
7:00 AM – 5:45 PM
Registration Open
7:30 AM – 8:00 AM
Opening Remarks & Presidential Address
- Julie Ann Sosa, MD, ATA President
- Jacqueline Jonklaas, MD, PhD, Secretary
- Amanda Perl, ATA Executive Director
- Alexandra M. Dumitrescu, MD, PhD, Program Committee Co-Chair
- Elizabeth Gardner Grubbs, MD, Program Committee Co-Chair
8:00 AM – 9:00 AM
Plenary – Year in Thyroidology
- Graham Williams, MD, PhD – Basic Science Year in Review
- Whitney Goldner, MD – Clinical Year in Review
- Catherine Sinclair, MD – Surgical Year in Review
9:00 AM – 10:00 AM
Highlighted Oral Abstracts
Co-Chairs: Meredith Hartley, PhD and Whitney Goldner, MD
- Kharisa Rachmasari, MD – “The Use of Medical Therapy for Thyroid Eye Disease in the Era of Teprotumumab”
- Cheng Han, PhD – “Assessment of iodine status in U.S. women of reproductive age and pregnant women: NHANES 2001-2020”
- Vera Tiedje, MD, PhD – “Tet2-mutant Clonal Hematopoiesis Drives Resistance to MAPK Inhibitors in BRAFV600E-mutant Anaplastic Thyroid Cancer”
- Elizabeth Cahoon, PhD – “Risk of thyroid nodules in residents of Ukraine exposed as children or adolescents to iodine-131 from the Chornobyl accident”
10:00 AM – 6:15 PM
Exhibit Hall Open
10:00 AM – 10:30 AM
Poster Review and Break
10:35 AM – 11:35 AM
Symposia (4 concurrent)
- Thyroid Subclinical Disease and Cardiovascular Risk
- Co-Chair: Paul Ladenson, MD
- Co-Chair: Layal Chaker, MD
- Gabriela Brenta, MD – Metabolic Mechanisms in Subclinical Hypothyroidism
- Anne Cappola, MD – Modifiers of CV risk in subclinical hypothyroidism
- Donald McLeod, PhD – The association of subclinical hyperthyroidism with CVD
- Understand Current Evidence for Redifferentiation Therapy
- Co-Chair: Aime Franco, PhD
- Co-Chair: Jim Fagin, MD
- Christopher McCabe, PhD – The history of redifferentiation therapies in treatment of thyroid cancers
- Alan L. Ho, MD, PhD – Clinical applications of redifferentiation therapies in treatment of RAI refractory thyroid cancers
- Naifa Lamki Busaidy, MD – Molecular mechanisms of resistance of thyroid cancer redifferentiation therapies
- Social Media for the Social Thyroidologist
- Co-Chair: Xiaoyin Jiang, MD
- Co-Chair: Arti Bhan, MD
- Melissa Young, MD
- Malini Gupta, MD
- Michael Yeh, MD
- Richard Ricciardi, PhD
- Deiodinases in Developmental Transitions and Thyroid Disorders
- Co-Chair: Antonio Bianco, MD, PhD
- Co-Chair: Silvania da Silva Teixeira, PhD
- Arturo Hernandez, MD – Deiodinases and brain development
- Tatiana Fonseca, PhD – D2 effect in the liver and epigenetic effect of T3
- Cristina Luongo, PhD – The role of the deiodinases in fibroadipogenic progenitors and muscle cells
11:35 AM – 12:45 PM
Poster Review and Lunch on Your Own
11:45 AM – 12:45 PM
12:55 PM – 1:45 PM
Ingbar & Braverman Award Lectures
- Yaron Tomer, MD – Sidney H. Ingbar Distinguished Lectureship Award, “The Role of Autophagy in Autoimmune Thyroiditis: A New Paradigm”
- Rosalind Brown, MD – Lewis E. Braverman Distinguished Lectureship Award, “Thyroid Disease in Children: A Fifty Year Perspective”
1:50 PM – 2:50 PM
Oral Abstracts
#1: Thyroid Cancer
Co-Chairs: Sana Ghaznavi and Sarimar Agosto Salgado
- Sarah Hamidi “Checkpoint Inhibition In Addition To DABRAFENIB + TRAMETINIB (DT) FOR BRAFV600E Mutated Anaplastic Thyroid Carcinoma (BRAFm-ATC)” (Oral 5)
- Myriem Boufraqech “The identification of novel genetic vulnerabilities in anaplastic thyroid cancer cells to overcome resistance to BRAFV600E inhibitor using a genome-wide CRISPR screen” (Oral 6)
- David Toro-Tobon “Efficacy and predictors of response to radioactive iodine redifferentiation therapy in previously iodine refractory papillary thyroid carcinomas” (Oral 7)
- Martin Read “Rational Drug Design of VCP Inhibitors to Enhance NIS Function in Radioiodide Therapy”(Oral 8)
#2: Thyroid Hormone Action and Regulation
Co-Chairs: Alex Dumitrescu and Anthony Hollenberg
- Randy Stout “A New Transgenic Mouse Line To Allow Testing The Relationships Between Thyroid Hormone, Mitochondrial Morphology, And Gap Junction Connectivity With Subcellular Precision” (Oral 10)
- Yuta Tanizaki “Liver Development During Xenopus Tropicalis Metamorphosis Is Controlled By T3-Activation Of WNT Signaling” (Oral 9)
- Ulrich Schweizer “Identification Of Human TRIAC Transmembrane Transporters” (Late Breaking Oral 37)
- Caroline Frädrich “Identification And Characterization Of Novel DIO2 Inhibitors By High-Throughput-Screening Of Small Molecule Libraries” (Late Breaking Oral 38)
#3: Effects and Treatment of Autoimmune Thyroid Disease
Co-Chairs Mizuho Mimoto and Cary Mariash
- Kimberly Cockerham “In Vitro Pharmacology and Phase 1/2 Results of VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor in Thyroid Eye Disease (TED)” (Oral 11)
- Carol Chiung-Hui Peng “Major cardiovascular outcomes of hyperthyroidism treated with antithyroid drug, radioactive iodine, or thyroidectomy: A Taiwanese national cohort” (Oral 12)
- Paola Mina-Osorio “Incidence of Thyroid Eye Disease in the United States: Analysis of a Healthcare Claims Database” (Oral 13)
- Julia Baran “Triiodothyronine Levels in Athyreotic Pediatric Patients During Levothyroxine Therapy: Is Monotherapy Adequate to Normalize Thyroid Hormone Levels?” (Late Breaking Oral 39)
3:00 PM – 4:00 PM
Exhibitor Networking Break
Diversity, Equity and Inclusion Networking Session
E. Chester Ridgway Trainee Conference: Basics of Thyroid Ultrasound (Trainees Only)
4:10 PM – 5:10 PM
Sawin Lecture – Celebrating ATA’s Centennial
- David S. Cooper, MD, Introduction
- Peter A. Kopp, MD, “The American Thyroid Association 1923 – 2023, Honoring our Past – Embracing our Future”
5:15 PM – 6:15 PM
Bobbi Smith Networking Social Hour – Celebrating ATA’s Centennial
AFTER 6:15 PM
NETWORKING/DINNER ON YOUR OWN
Friday, September 29, 2023
7:00 AM – 5:00 PM
Registration Open
7:00 AM – 7:45 AM
Thyroid & Pregnancy Guidelines Update
- Erik Alexander, MD, Co-Chair
- Carol Chiung-Hui, MD, Co-Chair
- Angela M. Leung, MD
- Tim Korevaar, MD, PhD
7:50 AM – 8:00 AM
Recognition of Stanbury Medal, Distinguished Service, and Women in Thyroidology Woman of the Year Awardees and Morning Announcements from Co-Chairs
- Carole Spencer, MD, PhD – John B. Stanbury Thyroid Pathophysiology Medal
- M. Regina Castro, MD – Distinguished Service Award
- Lisa Orloff, MD – Women in Thyroidology, Woman of the Year
8:00 AM – 9:00 AM
Plenary – Innovations in Research: Conversations for the Future
- Julie Ann Sosa, MD, Professor and Chair of the UCSF Department of Surgery and Leon Goldman, MD, Distinguished Professorship in Surgery
- Anthony N. Hollenberg, MD, John Wade Professor, Medicine & Chair of the Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Physician-in-Chief at Boston Medical Center
- Leah Hubbard, Ph.D., Program Director- Brain and Head & Neck/Thyroid SPOREs, Translational Research Program (TRP), Chief Diversity Officer Division of Cancer Treatment and Diagnosis (DCTD) National Cancer Institute
- Rebecca Schweppe, PhD, Professor of Medicine, Director, Cancer Biology Graduate Program and Research Director, Division of Endocrinology, Metabolism, and Diabetes, University of Colorado Anschutz School of Medicine
- Sarah Temkin, MD, Associate Director for Clinical Research, NIH Office of Research on Women’s Health
- Martha A. Zeiger, MD, Director of the Center for Cancer Research Office of Surgeon-Scientist Career Development at the National Institutes of Health
9:00 AM – 9:50 AM
Van Meter & Galton Award Lectures
- Anne Cappola, MD – Valerie Anne Galton Distinguished Lectureship Award, “Defining Thyroid Dysfunction: A Collaborative Approach”
9:50 AM – 4:00 PM
Exhibit Hall Open
9:50 AM – 10:20 AM
Poster Review and Break
10:20 AM – 11:20 AM
Symposia (4 concurrent)
- Endocrine Disrupting Chemicals and the Thyroid: High Time to Act
- Co-Chair: Heather Stapleton, PhD
- Co-Chair: Leonidas Duntas, MD
- Leonardo Trasande, MD, MPP – Endocrine disruptors and thyroid: human health and economic consequences, as well as needed policy actions
- Nicole Deziel, PhD – Environmental exposures and thyroid cancer risk: new epidemiologic findings
- Jennifer Sass, PhD – The endocrine disruptors screening program in the United States
- Clinical Application of Updated ATA Guidelines and ACR-TIRADS: Value and Limitations of Sonographic Assessment of Thyroid Nodules
- Co-chair: Jennifer Sipos, MD
- Co-chair: Cord Sturgeon, MD
- Susan Mandel, MD & Jill Langer, MD – Evolution and Current State of ACR TIRADS and ATA Sonographic Pattern System
- Merry Sebelik, MD – How to assimilate sonographic data, patient risk factors, and physical exam findings.
- Quality of Life in Patients with Thyroid Disease
- Co-Chair: Cari Kitahara, PhD
- Co-Chair: Ulla Feldt-Rasmussen, MD
- Ben James, MD – Patient-Reported Quality of Life Outcome Measures in the Thyroid Cancer Population
- Archana Radhakrishnan, MD – The Role of primary care in thyroid cancer survivorship
- Robin Peeters, MD – Quality of Life in Patients with Benign Disease
- The use of Thyroid Analogues in the Treatment of Non-Thyroidal Disease
- Co-Chair: Eveline Bruinstroop, MD
- Co-Chair: Meredith Hartley, PhD
- Soledad Bárez-López, PhD – Thyromimetic actions of Sobetirome and its Amide Prodrug Sob-AM2
- Riccardo Zucchi, MD, PhD – Thyroid hormone analogues: an update
- Josef Köhrle, PhD – How TH transmembrane transporters, deiodinases and T3 receptors contribute to action of T3 analogues
11:20 AM – 12:40 PM
Poster Review and Lunch on Your Own
11:30 AM – 12:15 PM
Meet the NIDDK Program Directors
- Henry Burch, MD, Program Director: Division of Diabetes, Endocrinology, & Metabolic Diseases
- Saul Malozowski, MD, PhD, Program Director: Division of Diabetes, Endocrinology, & Metabolic Diseases
11:30 AM – 12:30 PM
12:40 PM – 1:40 PM
Oral Abstracts
#4: Thyroid Cancer
Co-Chairs: Inigo Landa and Theodora Pappa
- Sophie Leboulleux “ESTIMABL 2 trial: Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer: 5 years of follow-up” (Oral 14)
- Lindsay Morton “Molecular Characteristics Distinguish Radiation-Induced Versus Sporadic Papillary Thyroid Carcinomas After the Chornobyl Nuclear Power Plant Accident” (Oral 15)
- Viktoria Florentine Koehler “Taking Advantage of the Interleukin-6-Biology in Differentiated Thyroid Cancer to Stimulate Sodium Iodide Symporter (NIS)-Mediated Iodide Uptake in Engineered Mesenchymal Stem Cells” (Oral 16)
- Linwah Yip “A Prospective, Multicenter Study of Molecular-Based Initial Thyroidectomy for Bethesda V/VI Cytology” (Oral 17)
#5: Surgery
Co-Chairs: Anastasios Maniakas and R. Michael Tuttle
- Anna Sawka “Decision Regret after Choosing Surgery or Active Surveillance for Management of Small, Low Risk Papillary Thyroid Cancer: Results of a Prospective Cohort Study” (Oral 18)
- Helena Levyn “Surgical and Oncologic Outcomes after Conversion Surgery for Patients with Low-Risk Papillary Thyroid Carcinoma Initially Followed with Active Surveillance” (Oral 19)
- Ian Hay “Can Ultrasound-Guided Ethanol Ablation Achieve Durable Long-Term Control of Recurrent Neck Nodal Metastases” (Oral 20)
- Michelle Lundholm “The Safety and Adequacy of Performing Ultrasound-guided Thyroid Nodule FNA Biopsy while on Anticoagulant and Antiplatelet Medications” (Late-Breaking Oral 40)
#6: Thyroid Hormone Action and Regulation
Co-Chairs: Zeina Hannoush and Randy Stout
- Xiaohan Zhang “Perturbation of Endoplasmic Reticulum Proteostasis Triggers Tissue Injury in the Thyroid Gland” (Oral 21)
- David Sharlin “Cochlear Development and Auditory Function in a Mouse Model of Allen-Herndon-Dudley Syndrome” (Oral 22)
- Liezhen Fu “Disruption of T3-Induced Epigenetic Regulator Mbd3 Leads To Growth Inhibition And Development Retardation In Xenopus” (Oral 23)
- Julia Maier “Into the Unknown: The Actions of Thyroid Hormone in the Zona Incerta” (Oral 24)
1:50 PM – 2:50 PM
Symposia (4 Concurrent)
- How can Neonatal Screening Keep up with Genetic Defects?
- Co-Chair: Ari Wassner, MD
- Co-Chair: Anita Boelen, PhD
- Samuel Refetoff, MD- Measurement of rT3 and rT3/T3 in dried blood spot samples at birth
- Paul van Trotsenburg, MD, PhD – Various neonatal screening approaches for CH
- Athanasia Stoupa, MD – Genetics of congenital hypothyroidism: Modern concepts
- Thyroid Hormone Mood and Cognition
- Co-Chair: Jacqueline Jonklaas, MD, PhD
- Co-Chair: Vishnu Sundaresh, MD
- Mark Frye, MD – The association between TH and mood disorders
- Jennifer Kruse, MD – T3 and depression
- Matt Ettelson, MD – Treatment of Hypothyroidism and the use of T3:is this beneficial for mood disorders?
- AI Chatbots – Ethical & Practical Implications
- JP Brito, MD – Background & Introductions
- David Toro-Tobon, MD – Examples of present and future uses of AI Chatbox in practice, research and scholarly activities
- Derek O’Keeffe, MD – AI Chatbox pitfalls and ethical considerations
- Managing Low Risk Thyroid Cancers – What’s the Right Answer in 2023?
- Co-Chair: Laura Boucai, MD
- Co-Chair: Leonardo Rangel, MD
- Carmen Solorzano, MD
- Timothy Huber, MD
- Wendy Sacks, MD
2:50 PM – 5:15 PM
ATA Surgical Symposium – “Controversies in Thyroidology: Value and Challenges of Multidisciplinary Team Approach”
- Panel 1 – “Case Discussions: Early Cancers and Nodules with Mutations”
- Co-Chairs: Elizabeth Cottrill, MD and Peter Angelos, MD
- Megan Haymart, MD
- Susan Pitt, MD
- Jonathon Russel, MD
- Panel 2 – Case Discussions: Advanced Differentiated and Medullary Thyroid Cancer”
- Co-Chairs: Lilah Morris-Weisman, MD and Mark Zafereo, MD
- Erin Buczek, MD
- Melanie Goldfarb, MD
- Virginia Livolsi, MD
- Mabel Ryder, MD
- Co-Chairs: Lilah Morris-Weisman, MD and Mark Zafereo, MD
- Co-Chairs: Elizabeth Cottrill, MD and Peter Angelos, MD
2:50 PM – 4:00 PM
Exhibitor Networking
3:00 PM – 4:00 PM
Expo Theater >
E. Chester Ridgway Trainee Conference: Bench to Bedside Case Presentations: Hypothyroidism Case and Hyperthyroidism Case (Trainees Only)
Special Interest Networking Sessions
- Artificial Intelligence Networking Session
- Co-Chair: Juan P. Brito, MD
- Co-Chair: Nakkay Singh Ospina, MD
- Co-Chair: David Toro-Tobon, MD
- Mouse models/Basic Science Meet Up
-
Co-Chair: Megan Ritter, MD
-
Co-Chair: Sheue-yann Cheng, PhD
-
4:05 PM – 4:50 PM
Discussion-Debates/MTP Workshops (4 concurrent)
- Cancer Syndrome with Non-Medullary Thyroid Cancer
- Co-Chair: Ana Hoff,
- Co-Chair: Steven Waguespack, MD
- Electron Kebebew, MD – Genetics, screening and management of inherited syndromes associated with non-medullary thyroid cancer
- Huiying Wang, MD – Diagnostics of thyroid nodules and cancer in patients with familial syndromes
- Impact of Drugs on Thyroid Physiology
- Co-Chair: Julie Hallanger Johnson, MD
- Co-Chair: Ramona Dadu, MD
- Anupam Kotwal, MD – Win some, lose some: Cancer therapy and the thyroid
- Daniele Cappellani, MD- Amiodarone and the Innocent Thyroid
- Change in Treatment of Hyperthyroidism Over the Century
- Co-Chair: Karen Tsai, MD
- Co-Chair: Michael McDermott, MD
- John C. Morris, MD – Endocrine history of treatment of hyperthyroidism & pioneers
- Merry Sebelik, MD – Surgical history of treatment of hyperthyroidism
- New omic Approaches in Understanding Thyroid Disease
- Co-Chair: Jeffrey Knauf, PhD
- Co-Chair: Myriem Boufraqech, PhD
- Tom Giordano, MD, PhD – Integrated omics in in PTC and FTC
- Erik S. Blomain MD, PhD – Omics in thyroid tumorigenesis and treatment response
5:00 PM – 6:00 PM
5:15 PM – 5:45 PM
ATA Annual Membership Meeting (Formerly Annual Business Meeting)
AFTER 5:45 PM
NETWORKING/DINNER ON YOUR OWN
Saturday, September 30, 2023
7:00 AM – 5:00 PM
Registration Open
7:00 AM – 7:45 AM
Training Program Director Networking Session
7:45 AM – 7:50 AM
Morning Announcements from Co-Chairs
7:50 AM – 8:50 AM
Plenary – Diversity, Equity and Inclusion in Medicine & Academics: Reflections & A Call to Action
- Panel Discussion
- Carmelo Nucera, MD, PhD – Co-Chair
- Sanziana Roman, MD – Co-Chair
- Julie Ann Sosa, MD
- Naifa Busaidy, MD
- M. Regina Castro, MD
- David Steward, MD
- Joanna Miragaya, MD
8:50 AM – 9:50 AM
Women in Thyroidology Plenary
-
Marie A. Bernard, MD, Chief Officer for Scientific Workforce Diversity, National Institutes of Health
9:50 AM – 1:00 PM
Exhibit Hall Open
9:50 AM – 10:20 AM
Poster Review and Break
10:25 AM – 11:25 AM
Symposia (4 concurrent)
- Research Grant Session
- Thyroid and Aging, Treatment in Older Adults
- Co-Chair: Thanh Hoang, MD
- Co-Chair: Sina Jasim, MD
- Jenna Mammen, MD – How thyroid function tests change with aging
- Maria Papaleontiou, MD – Considerations in titrating treatment in older individuals
- Giuseppe Barbesino, MD – Special considerations about Graves’ disease in older individuals
- Treatment of ATA Intermediate Risk DTC
- Co-Chair: Mara Roth, MD
- Co-Chair: Dave Steward, MD
- Cosimo Durante, MD – Post-Operative Management of Intermediate Risk DTC: Short Term and Long-term
- Abbey Fingeret, MD – Surgical Decision Making in the Treatment of Intermediate RiskDTC
- The Roles of Autophagy and Thyroid Hormone in the Pathogenesis and Treatment of NAFLD
- Chair: Gregory A. Brent, MD
- Paul Yen, MD – Thyroid hormone regulation of autophagy and NAFLD
- Joao Anselmo, MD – The risk of NAFLD in Resistance to Thyroid Hormone beta (RTHT beta)
- Eva Wirth, PhD – Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis
11:25 AM – 12:40 PM
Poster Review and Lunch on Your Own
11:30 AM – 12:30 PM
Expo Theater >
Multicenter Clinical Trials Networking Session
12:40 PM – 1:40 PM
Plenary – Artificial Intelligence
- Co-Chair: Trevor Angell, MD
- Co-Chair: Johnson Thomas, MD
- Nestoras Mathioudakis, MD, The Current State of AI and Future Applications of AI in Medicine and Beyond
- Marco Alvarez, MD, Artificial Intelligence in Thyroid Nodule and Thyroid Cancer Imaging
- Naykky Singh-Ospina, MD, Use of AI in Disorders of Thyroid Function: Graves’ Disease, Thyroid Eye Disease, Hashimoto, and Hypothyroidism
1:50 PM – 2:50 PM
Expo Theater >
Oral Abstracts
#7: Technology & Thyroid
Co-Chairs: Nikta Pozdeyev and David Toro Tobon
- Eun Ju Ha “AI-Thyroid: Pilot Results for Evaluating Thyroid Malignancy in Children” (Oral 25)
- Andrew Thomas “Novel Integration of Topological Data Analysis Into a Multimodal Machine Learning Model to Predict Follicular Carcinoma on Ultrasound” (Oral 26)
- Moon Jae Hoon “Performance validation of a machine learning-assisted system for predicting clinical activity score in thyroid-associated orbitopathy and comparison with ophthalmologists” (Oral 27)
- Daniel Campbell “Evaluating ChatGPT Queries on Thyroid Nodules for Patient Education” (Oral 28)
#8 Thyroid Nodules and Goiter
Co-Chairs: Poorani Goundan and Mark Lupo
- Ai Yoshihara “Long-term clinical outcomes after radioactive iodine treatment for an autonomous functional thyroid nodule” (Oral 29)
- Maria Mavromati “Unnecessary thyroid surgery rate in the absence of molecular testing” (Oral 30)
- Mason Stillman “Molecular Testing for Bethesda III Thyroid nodules: Trends in Implementation, Cytopathology Call Rates, Surgery Rates, and Malignancy Yield at a Single Institution” (Oral 31)
- Melbin Thomas “False-Negative Biopsy Rates Are Not Increased for Thyroid Nodules >4 cm if Non-Surgical Management is Included in Analysis” (Oral 32)
#9: Quality of Life & Health Disparities
Co-Chairs: Carrie Cunningham and Stephanie Fish
- Thomas Szabo Yamashita “Patient Reported Outcomes: What symptoms do long term thyroid cancer survivors experience?” (Oral 33)
- Hattie Huston-Paterson “Rural-urban Disparities in the Continuum of Thyroid Cancer Care: Analysis of 92,794 cases” (Oral 34)
- Gerasimos Sykiotis “Predictors of Poor Emotional Quality of Life in Patients with Differentiated Thyroid Cancer – Results of a Prospective International Study. “(Oral 35)
- Debbie Chen “Barriers to Getting in The Door for Thyroid Cancer Care” (Oral 36)
2:00 PM – 5:00 PM
ATA Pediatric Thyroid Symposium
- Percutaneous Approaches to Neoplastic Thyroid Disease in Children: Who and When?
- Chair: Chelsey Baldwin, MD
- Speaker: Jennifer Kuo, MD
- Pediatric Abstract Highlights
- Co-Chair: Larry Fox, MD
- Co-Chair: Zoltan Antal, MD
- Einas Alkhatib, MD – Pediatric Graves’ Disease: Improvement of Free T4 in Newly Diagnosed Patients Through a Multifaceted Quality Improvement Approach
- Julia Baran – Incidental Papillary Thyroid Microcarcinomas in Pediatric Patients Following Definitive Treatment for Graves’ Disease
- Alyssa Webster, MS – Recurrent or Persistent Thyroid Carcinoma in the Pediatric Population after Radioactive Iodine Treatment: A Systematic Review and Meta-Analysis
- Pediatric Tumor Board
- Co-Chair: Scott Manning, MD
- Co-Chair: Christine Cherella, MD
- Priya Vaidyanathan, MD
- Jeff Rastatter, MD
- Managing Children with Moderate Risk MEN2A
- Chair: Jonathan Wasserman, MD
- Speaker: Rosa Elisei, MD
3:00 PM – 3:50 PM
Highlighted Posters
#1: Thyroid Cancer & Surgery
Co-Chairs: Benjamin Gigliotti and Mimi Hu
- Justyna Gleba “Targeting Aggressive Thyroid Cancers with TSHR CART Cells” (Highlighted Poster 100)
- Debora Thomaz “Plasma-Based Genotyping For Monitoring Patients With Thyroid Cancer” (Highlighted Poster 101)
- Highlighted Poster 102 – Withdrawn
- Marin Kheng “Reoperation Rates after Initial Thyroid Lobectomy for Patients with Thyroid Cancer: A National Cohort Study” (Highlighted Poster 103)
- Jennine Weller “Few Patients With Medullary Thyroid Cancer Undergo Genetic Testing or Counseling” (Highlighted Poster 104)
- Ludovico Sehnem “Longitudinal Thyroid Ultrasound Screening in Patients with Familial Adenomatous Polyposis: Surveillance Recommendations” (Highlighted Poster 105)
#2: Thyroid Cancer, Pregnancy & Development, Health Disparities / Health Equity
Co-Chairs: Soffie Bliddal and Angela Leung
- Alaina Carr “Psychometric Evaluation of a New Instrument to Assess the Symptoms Following Radioactive Iodine Therapy among Patients with Differentiated Thyroid Cancer: SAlivary, LAcrimal, NaSal (SALANS) Questionnaire” (Highlighted Poster 106)
- Christian Hernandez-Padilla “BRAF Alterations are Linked to Changes in Thyroid Cancer Motility and Contractility in Nanofibrous Substrates with Tunable Fiber Spacing and Durotactic Regions” (Highlighted Poster 107)
- Enrique González-Madrid “Gestational hypothyroxinemia induces an acute inflammatory state at the maternal-fetal interface and produces an autistic-like phenotype in the offspring with more accentuation in males.” (Highlighted Poster 108)
- Jordan Ross “Improving Management of Congenital Hypothyroidism through Quality Improvement Cycles” (Highlighted Poster 109)
- Judy Qiang “Association between serum Thyroid Stimulating Hormone (TSH) and Cancer Recurrence among Adult Patients with Differentiated Thyroid Cancer (DTC): A Retrospective Cohort Study” (Highlighted Poster 110)
- Jiangnan Hu “Targeting Ferroptosis in BRAFV600E-Mutant Anaplastic Thyroid Cancer – A Novel Treatment Strategy” (Late Breaking Highlighted Poster 117)
#3: Disorders of Thyroid Function, TH Action, Metabolism and Regulation, Thyroid Imaging
Co-Chairs: Raquel Cano and Megan Ritter
- Ziyu Zhu “Exploring the Effects of Thyroid Hormones on Oligodendrocyte Progenitor Cell Differentiation for Potential Therapeutic Use in Myelin Repair” (Highlighted Poster 111)
- Highlighted Poster 112 – Withdrawn
- Maryam Mansoori “THYROID AND THE BRAIN – TSH ENHANCES NEURITE OUTGROWTH” (Highlighted Poster 113)
- Jaemin Park “Cost-Effectiveness of a Digital Therapeutic for Managing Hyperthyroidism: Evaluation of GlandyTM” (Highlighted Poster 114)
- Highlighted Poster 115 – Withdrawn
- Highlighted Poster 116 – Withdrawn
4:05 PM – 4:50 PM
Discussion-Debates/MTP Workshops (3 concurrent)
- Oncocytic Tumors – New Definition and How They Differ from Previous Classifications
- Co-Chair: Kartik Viswanathan, MD, PhD
- Co-Chair: Marina Nikiforova, MD
- Esther Diana Rossi, MD – Updates on WHO classification and FNA diagnostics of oncocytic tumors
- Ian Ganly, MD – Molecular genetics and therapeutic approaches to oncocytic tumors
- Management of Patients with Thyroid Disorders Undergoing IVF
- Chair: Tim Korevaar, MD, PhD
- Kristien Boelaert, MD, PhD – Subclinical hypothyroidism and thyroid auto-antibodies in women with subfertility or recurrent pregnancy loss
- Jennifer Eaton, MD – Thyroid hypofunction and autoimmunity in women undergoing assisted reproductive technology
- Tumor vulnerability: rationale for combined therapy in BRAFV600E thyroid cancers
- Co-Chair: Carmelo Nucera, MD, PhD
- Co-Chair: Maria Cabanillas, MD
- Rebecca Schweppe, PhD – Preclinical models to sensitize BRAFV600E pathway inhibitors and overcome resistance of thyroid cancer cells
- Lori Wirth, MD – Precision thyroid oncology for patients: therapeutic implementations tackling refractoriness to BRAFV600E inhibitors and TKIs
5:00 PM – 8:00 PM
NETWORKING/DINNER ON YOUR OWN
8:00 PM – 11:00 PM
ATA Centennial Celebration Party (Additional registration required)
- Join us for an evening of dancing and karaoke as we celebrate the ATA’s Centennial. Party refreshments and snacks will be served.
Sunday, October 1, 2023
8:00 AM – 11:00 AM
Registration Open
8:15 AM – 9:15 AM
Parallel Sessions
- Tumor Board
- Co-Chair: Tracy Wang, MD
- Co-Chair: Lindsay Bischoff, MD
- Marika Russell, MD
- Bryan McIver, MD
- Robert Flavell, MD
- Peter Sadow, MD
- Genetic Defects in Humans and Mice Affecting Thyroid Function
- Co-Chair: Peter Arvan, MD, PhD
- Nadia Schoenmakers, MD, PhD – Homozygosus loss-of-function mutations in SLC26A7 cause goitrous congenital hypothyroidism
- Mingyao Liu, MD – Role of XB130 in normal thyroid function
- Gerasimos Sykotis – The Keap1/Nrf2 signaling pathway in the thyroid
9:15 AM – 11:15 AM
Parallel Sessions
- Arthur Bauman Symposium – Insights Into the New ATA Guidelines
- Co-Chair: Ellen Marqusee, MD
- Co-Chair: Spyridoula Maraka, MD
- Thyroid Nodules: Lisa Orloff, MD & Susan Mandel, MD
- Differentiated Thyroid Cancer: Julie Ann Sosa, MD & Matt Ringel, MD
- Pediatric Thyroid Cancer: Jonathan Wasserman, MD, Andy Bauer MD, & Steven Waguespack, MD
- Basic/Translational Symposium
- Recent Progress on the Effect of Thyroid Hormone Signaling in Development in Animal Models
- Co-Chair: Yun-Bo Shi, PhD
- Co-Chair: Salma Khan, PhD
- David Parichy, PhD – Thyroid hormone regulation of skin morphogenesis in zebrafish
- Sheue-yann Cheng, PhD – TR mutant zebrafish
- Douglas Forest, PhD – Thyroid hormone signaling in mouse visual/auditory development
- Thyroid Hormone Transporters
- Co-Chair: Edward Visser, MD
- Co-Chair: Ulrich Schweizer, PhD
- Stefan Groeneweg, MD, PhD – MCT8 deficiency: integrated genomic, functional, structural and predictive insights
- Ana Guadano-Ferraz, PhD – A knockin mouse model for Mct8 deficiency.
- Federico Salas-Lucia, PhD – New Roles for MCT8 on Brain Development and Function
- Recent Progress on the Effect of Thyroid Hormone Signaling in Development in Animal Models
11:15 AM
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.